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Abstract: Polypharmacy is becoming increasingly common, especially among the elderly. It often
has a negative connotation, but is sometimes necessary or even desirable, and needed to categorize
polypharmacy as appropriate or inappropriate. The challenge is in ensuring that this is considered
appropriate when necessary. We aimed to develop an evidence-based intervention to reduce the
risks associated with using a systematic approach, involving key stakeholders in prescribing and
dispensing drugs to the elderly in primary care. The purpose of this study is to identify the key
components which are perceived as influencing these behaviours. It is a qualitative study of general
practitioners (GPS) and community pharmacists involved in the care of the elderly. The main
inclusion criterion is the geographic location. Qualitative data will be generated from one-on-one,
semi-structured interviews and processed for thematic content analysis. Our approach integrates
the patient pathway in primary care. It considers the fact that GP and pharmacist behaviours are
far from being independent. This study represents the first step in the process of developing an
intervention theory which involves a crossover between data from the literature and the knowledge
of experts, allowing us to interrogate hypotheses about the influences and mechanisms associated
with prescribing and dispensing drugs to the elderly in primary care.
Keywords: polypharmacy; aging; qualitative study; intervention; prescribing; dispensing; theoretical
domains framework
1. Introduction
The use of medications is increasing, especially among the elderly. This increase is
mainly attributed to the high prevalence of multi-morbidity, with 50% of adults aged 75
and older now living with at least three concomitant conditions [1] and the broadening
of therapeutic options, with an increasing number of clinical practice recommendations
calling for the use of more than one drug in the management of chronic diseases [2–4].
Polypharmacy has been identified as the main determinant of potentially inappropriate
prescribing among the elderly. It is associated with many negative clinical consequences
caused by adverse drug events, but also with the decreased efficacy of treatments or
a decreased adherence to treatments. Polypharmacy also has economic implications,
including the cost of reimbursing potentially ineffective treatments and the cost of cascading
complications [5,6].
There is no universally accepted definition of the term “polypharmacy”. Much of the
literature to date has referred to numerical thresholds, such as the concomitant prescription
of four or five drugs. However, recent studies have highlighted the need to take the clinical
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context in which drugs are prescribed into account. Therefore, the concept of inappro-
priate use of multiple medications should be preferred over the existing threshold-based
definitions [7]. Appropriate polypharmacy is defined as “prescribing for individuals with
complex or multiple conditions where drug use has been optimized and prescribing is
consistent with the best available evidence”. The concept of “inappropriate multiple medi-
cations”, therefore, recognizes that patients can benefit from multiple medications if the
prescription is evidence-based and reflects the clinical needs of the patient [5]. However,
these definitions are still based on relatively imprecise concepts, such as “evidence-based”
or “clinical needs”. A recent review identifies studies the literature that have defined appro-
priate or rational polypharmacy, or have recognized the distinction between appropriate
and inappropriate medications [8]. These studies either defined polypharmacy using a
brief description only, or used a brief description and polypharmacy tools, such as the
Beers criteria and the Medication Appropriateness Index (MAI) [9–14]. Nevertheless, none
of these definitions explicitly allow us to identify any list of behaviours classified as ‘inap-
propriate’ in terms of prescribing and dispensing drugs. Therefore, to achieve appropriate
medication for the elderly, our approach must be multidimensional. This requires the
merging of different disciplines because inappropriate polypharmacy is the result of the
combination of several factors, which go far beyond the drug’s appropriateness [15].
Our hypothesis is that, in these complex situations, an intervention targeting the
main determinants of inappropriate polypharmacy could reduce the associated risks. As
such, we chose to investigate the types of approach that could improve the process of
prescribing and dispensing medication for the elderly when their state requires more than
one medication to be taken. We are specifically interested in the behaviour of general
practitioners (GPs) and pharmacists, who, as primary health care providers, are poised to
play a pivotal role mitigating this growing issue.
In France, both GPs and community pharmacists are considered as primary care
providers. Since 2005, GPs have been given a soft gatekeeper role. Patients must designate
a médecin traitant, who is a GP in the vast majority of cases [16–18]. Said GP will be their
first point of contact with the health care system. He/she provides referrals to other health
professionals (i.e., specialist doctors, providing ambulatory and hospital-based care) and
seeks to develop a person-centered approach, ensuring continuous and long-term care [19].
Community pharmacists dispense medication and provide advice. As of March of 2018,
community pharmacists have been mandated to support elderly people who are prescribed
multiple medications, in close collaboration with GPs. The implementation of “Bilan
partagé de médication”, which consists of a structured critical analysis of the patient’s
medications with the objective of establishing a consensus with the patient regarding his or
her treatment, taking care to optimize the clinical impact of the medications, reduce the
number of problems related to the therapy, and reduce unnecessary extra costs, has truly
formalized the shared follow-up of the elderly [20,21].
The research protocol described within is part of a broader research project with the
aim of designing and developing an evidence-based, and inherently complex, intervention
to reduce the risks associated with inappropriate polypharmacy. Our research project is
organized in several phases. The purpose of this one is to develop a theory-based interven-
tion using a systematic approach guided by the best available evidence and appropriate
theory, and involving key stakeholders involved in prescribing and dispensing drugs to
elderly patients in primary care (i.e., GPs and community pharmacists). The aim of this
specific study is to identify and select the key components (mechanisms and activities)
perceived as influencing the prescription and dispensing of appropriate polypharmacy.
2. Materials and Methods
2.1. The Underlying Theoretical Model
Public health, as well as other disciplines, has grasped the concept of complexity.
This consideration, more instrumental than conceptual, of this notion in the field of health
extends to the design and evaluation of so-called complex interventions. They are complex
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because they are supposed to act on behaviours that cannot be dissociated from their
contexts or the systems to which they belong [22]. The Medical Research Council (MRC)
emphasizes, according to the same principle, that an intervention is made up of several
components that interact with each other and the context in which they take place. The
MRC proposes the use of theory-based approaches for the evaluation and development of
interventions [23–25].
Our approach has been modelled on these recommendations, and the underlying
theoretical model is the theoretical domains framework (TDF). The TDF is founded in the
psychological theory of behaviour change. By simplifying these concepts, researchers from
non-health-psychology backgrounds can access behavioural theories [26]. Two versions
exist: one with 12 theoretical domains and a second, more recent, and refined version with
14 domains [27]. In the appendix (i.e., Appendix A), a flow chart illustrates the two different
versions of TDF. The first version of the TDF remains the most widely used version. This is
the one we have chosen for our study [28–31]. Thus, the 12 theoretical domains that make
up the TDF (v 1.0) and are relevant to changing behavioural health care professionals are:
knowledge; skills; social/professional role and identity; beliefs about capabilities; beliefs
about consequences; motivation and goals; memory, attention and decision processes;
environmental context and resources; social influences; emotion; behavioural regulation;
nature of the behaviours [26]. For our intervention on targeting prescribing and dispensing
behaviour, the TDF v 1.0 will be used to identify key theoretical domains (mechanisms
of interactions) that are perceived to influence providers’ behaviours and provide a solid
evidence base to guide the intervention design. The key components will then be correlated
with the behaviour change techniques (BCTs) that may form the “active ingredients” of the
intervention (activities) using the S. Michie taxonomy [32].
2.2. Study Design
This is a qualitative study. Data will be collected through individual semi-directive
interviews. This method of data collection is used to collect information from individuals
about their own practices, beliefs, or opinions, to gather information on past or present
behaviours or experiences and to tap into the expert knowledge of an individual. These in-
terviews will likely gather factual material and data, such as descriptions of processes [33].
Individual semi-structured interviews also allow professionals the freedom to express
their views on their own terms. It is also an appropriate data collection method when
seeking to explore the perception and representation of GPs and pharmacists regarding
polypharmacy use in the elderly, where our analysis will aim to explore their approaches
to prescribing and dispensing polypharmacy in this age group, and their perceptions
of barriers and facilitators to achieving appropriate polypharmacy in elderly patients in
ambulatory care.
Semi-directive interview guides based on the 12 domains of the TDF will be used.
Open-ended questions will be favored, in order to obtain individualized answers while
ensuring that the themes covering the 12 domains are well addressed. The interviews will
be conducted by the doctoral student (NT). Interviews will be recorded and then transcribed
into a text file. An analysis of qualitative data will be carried out in collaboration with
other members of the research team.
Data collection for this study commenced in November 2020, and analyses are planned
to be completed by the end of July 2021.
2.3. Constitution of the Panel
With the objective of understanding reality, our goal is not to establish a representative
sample, but rather to identify individuals who possess relevant characteristics that allow
us to explore the aspects of the studied phenomenon in depth [34].
The representation that interests us in this qualitative study is a representation of
the perspectives, meanings, opinions and ideas of general practitioners and pharmacists
with regard to the subject under study. The selected panel does not concern a population
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composed of individuals, but a phenomenon, the lived meaning of which we want to
identify [35].
2.3.1. Selection Criteria
To serve the objective of our qualitative study, the essential characteristics are, there-
fore, intentionality and pertinence to our research question [34]. Based on the idea of
approaching “competent” GPs and pharmacists, who are likely to provide the most rele-
vant information with regard to our initial questions and to capture the variability in the
discourse on the subject under investigation, which is prescribing and dispensing drugs
to the elderly in primary care, the main selection criterion was the geographic location of
the medical office and pharmacies in which the GPs and pharmacists practice. We aimed
to target different geographical areas with a large population of elderly people (aged 60
and over).
2.3.2. Target Population
Data from The French National Institute of Statistics and Economic Studies (INSEE)
describe the populations of different regions according to age. Nouvelle Aquitaine is the
oldest region in France, with 29% of people aged 60 or over (compared with the national
average of 25%); almost all of these seniors (95%) live at home [36]. Based on the available
INSEE data, seven areas (i.e., Table 1) with an aging population, specifically municipalities
where the proportion of the population aged 60 or over exceeds 40%, were targeted [37].
Table 1. Selected Areas in Nouvelle-Aquitaine.
Areas Municipalities Departments
Area 1 Arcachon Gironde
Area 2 Soulac-sur-Mer, Le Verdon, Arès Gironde
Area 3 Biarritz Pyrénées-Atlantiques
Area 4 Soorts-Hossegor Landes
Area 5 Cantons d’Eymet, St-Alvère et Domme Dordogne
Area 6 Cantons de Lauzun, Villeréal, Castillonnès Lot-et-Garonne
Area 7 Cantons de Hautefort, Jumilhac-Le-Grand, St-Pardoux-La-Rivière,Bussière-Badil, Mareuil, Verteillac, Saint-Aulaye Dordogne
The constitution of the panel of providers will be conducted in two steps.
2.3.3. Recruitment of General Practitioners
GPs were identified in the geographical areas previously defined using the Yellow
Pages. Lists will be drawn up and a random selection of doctors to contact will be made.
An initial contact will be established by phone. NT will provide potential participants with
a brief overview of the study, and answer any questions. Thereafter, an invitation letter and
an information sheet with a summary of the project will be sent to those who expressed
a wish to receive additional information. Finally, the interviewer (NT) will find the most
convenient place and time for a face-to-face interview with the GPs who consented. If
necessary, particularly in the context of the COVID-19 epidemic, the interviews may also
be conducted over the phone.
2.3.4. Recruitment of Dispensing Pharmacists
The choice was made to select pharmacists in a second stage from the network of
recruited GPs. In this manner, the recruited physicians will be asked to identify the local
pharmacies that dispense most of the prescriptions for elderly patients in the practice. In
the same way as for GPs, pharmacists will be contacted by phone by NT, who will provide a
brief summary of the project and send additional information to those who have requested
it. Appointments will be made, and interviews will be conducted, either in person or over
the phone, with consenting pharmacists.
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In all cases, written, informed consent will be obtained from all subjects.
2.3.5. Panel Size
An initial panel size is estimated, but the size of the final panel will be determined by
data saturation, meaning that no new information or themes emerge from the data and that
the interview n + 1 does not provide anything new compared to the interview n [38–40].
This is implied in the protocol to transcribe and code the interviews as they are conducted.
In total, there will be two groups, containing 14–20 GPs (ideally two and at least one from
each of the seven zones) and 7–10 pharmacists (at least one from each of the seven zones).
This will provide a total panel of 21–30 participants as an initial estimation. However,
practical issues such as time or resource constraints, ethical precautions, or accessibility of
the professionals to be interviewed may influence the final configuration of our panel.
2.4. Data Collection
2.4.1. Topic Guides
A first phase of the research project, preceding this survey, consisted of exploring the
existing scientific evidence, namely from other countries, and contextual and experiential
knowledge about proven or promising interventions related to the issue of inappropri-
ate polypharmacy.
More specifically, a large multi-phase research project has been conducted since 2015
by an Irish team, focusing on the development of interventions using a combination of evi-
dence and theory to address inappropriate polypharmacy in the elderly [28]. One phase of
this project resulted in the development of two interview guides based on the 12 domains of
TDF, one for GPs (to study prescribing behaviour) and anther one for pharmacists (to study
dispensing behaviour). Each topic guide includes a series of similar questions covering
four key areas: professionals’ views on the term ‘polypharmacy’; professionals’ assessment
of a clinical scenario depicting an older patient receiving inappropriate polypharmacy;
professionals’ perceptions of barriers and facilitators to ensuring the prescribing (GPs)
and dispensing (community pharmacists) of appropriate polypharmacy to older people;
professionals’ views on potential intervention components and outcome measures for
inclusion in future intervention studies. These interview guides were tested, validated,
and used during the survey conducted by the Irish research team and published with the
results of the survey [41].
Our strategy was to use these guides validated by a researchers’ consensus and to
adapt them to the needs of the present survey in France. The adaptation of these guides
was not limited to translation into French. It also consisted of modifying the questions to
be compatible with the context of France. A first version of these two adapted interview
guides was elaborated by NT and discussed with the fellow researchers. They were piloted
beforehand, during one-on-one interviews with two doctors and two pharmacists who are
not part of the sample. If required, questions were reworded, clarified, or completed in
order to obtain final versions.
2.4.2. Interview Process
NT will conduct semi-structured interviews with recruited professionals either at their
place of work, at another convenient location or by phone. Interviews take about 45 min.
A presentation is scheduled at the beginning of each interview and the agreement of
the participant will be obtained before starting.
Interviews will be audio-recorded in full using a voice recorder, and additional infor-
mation will be noted manually. At the end of the interview, an open-ended question will be
asked at in order to collect any comments from the participants about the interview process.
At the end of the interview, and as soon as possible, non-verbal aspects will be noted, as
well as general impressions of the interview process. A verbatim transcript will be made to
faithfully reflect the entire content of the interview. The quality of the transcription will be
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checked for each recording. Recordings will be separated into two groups to distinguish
the interviews of the doctors from those of the pharmacists, before being anonymized.
2.5. Analysis
We will employ thematic content analysis. The process of content analysis allows
for the replacement of an intuitive or instinctive interpretation of a given message with
a constructed one [42]. More specifically, a thematic analysis will be more conducive to
our research because it is about identifying, in the multiform and varied content of an
interview, the core of the meanings, to obtain a unique and original analysis of the themes
we will have defined beforehand, and possibly specified by professional discourse [43].
NVivo software will be used to facilitate data analysis. There will be a stage where
the transcripts are read and reread, without listening to the interview recordings. The
transcripts will first be read, checked, and analysed by the NT and another member of the
research team, as a validity check, will independently analyse at least 25% of the transcripts.
A two-step analysis will be adopted. First, a deductive approach using pre-defined
coding categories. Second, an inductive approach in which the emerging content themes
relating to barriers and facilitators within each domain were identified. The output from
the analysis should allow us to identify key theoretical domains and select BCTs.
2.6. Data Protection and Ethics
Audio-recordings will be anonymized, with all identifiable information removed prior
to using the software analysis tool. All audio-recordings will be destroyed immediately
after transcription and the data will be stored on a server at the University of Lyon 1
according to the current standards and conditions. Ethical approval for this study protocol
was obtained from the Ethics Committee of the University College of General Medicine
(CUMG, University of Lyon, n◦IRB: 2 July 2020).
3. Discussion
Close collaboration between general practitioners and pharmacists in primary care
is one of the cornerstones of the multidisciplinary approach, which is recommended
in order to optimize the care of the elderly. In France, cooperation between healthcare
professionals is a major incentive of the current French national health strategy, “Ma santé
2022”, launched in September 2018. Improved collaboration between healthcare providers
aims to optimize care pathways, and thus meet the expectations of both patients and
providers [44,45]. With regards to the collaboration between GPs and pharmacists, various
programs, initiated by the providers or of governmental origin, such as the PAERPA
program (Parcours des personnes âgées en risque de perte d’autonomie—care pathways
for older people at risk of loss of autonomy), have led to the development of collaborative
processes which bring GPs into contact with pharmacists in the context of daily inter-
professional communication [46,47]. This collaboration is promoted and reinforced by tools
such as the medication review (Bilan partagé de médication) which, even more specifically,
involves a collaboration between GPs and pharmacists for the management of elderly
people experiencing polypharmacy [21]. Although this collaboration remains, in fact,
largely informal, we have intended to capitalize on it in the design of this formative research
study by deliberately recruiting pharmacists from the network of previously recruited
physicians. Although our analysis approach will not take strict physician/pharmacist pairs
into account, this recruitment strategy allows for a selection of providers involved in the
care, to a certain extent, of the same elderly population. As the two behaviours, prescribing
and dispensing drugs, are far from being independent of each other, we have considered
the patient pathway in our approach.
4. Conclusions
This step of identifying and selecting the key mechanisms perceived to influence the
prescribing and dispensing of appropriate polypharmacy is a building block in the process
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of developing an intervention theory targeting these behaviours. This process involves
crossing data from the literature and the knowledge of experts (GPs and pharmacists in our
case) in a structured approach. The review of the literature can find evidence and define
hypotheses. The objective of crossing this with the expertise of professionals is to verify
these hypotheses, explaining which components (activities) can influence the targeted
behaviours and which mechanisms they use, and to adapt these hypotheses according to
the context. The finalized intervention theory (the expected outcome) will consist of an
analytical grid composed of x activities (BCTs), which activate x mechanisms influencing
the behaviour of GPs (prescription of appropriate polypharmacy for the elderly) and
pharmacists (dispensing of appropriate polypharmacy for the elderly).
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Appendix A. The Theoretical Domains Framework (Version1 (19) and Version2 (20)) with Definitions and
Component Constructs
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